July 24, 2017 07:04 AM EDTUpdated 07:19 AM
Deals

Mit­subishi Tan­abe bags Neu­ro­Derm and its PhI­II Parkin­son’s pro­gram for $1.1B

John Carroll

Editor & Founder

Mit­subishi Tan­abe is gob­bling up the Is­raeli biotech Neu­ro­Derm $NDRM, of­fer­ing an ear­ly morn­ing taste of the M&A ac­tiv­i­ty that has been woe­ful­ly short …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: White House threat­ens ‘most fa­vored na­tion’ plan to low­er US drug prices, but many ques­tions re­main

Trump says he'll sign or­der on 'most fa­vored na­tion' drug price plans Mon­day

Ex­clu­sive: Patrick Hsu start­up launch­es, looks be­yond CRISPR for gene in­ser­tion tech­nol­o­gy

Lil­ly says fur­ther head-to-head tri­al da­ta back Zep­bound over No­vo’s We­govy

Vir’s hep B dis­ap­point­ment, Ipsen's new Iqir­vo da­ta, plus more from #EASL25

FDA clears in vi­vo blood stem cell edit­ing tri­al; Abeon­a's $155M PRV sale

A service from the Financial Times